A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial T.E.S.T. in France between 2004 and 2012Report as inadecuate




A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial T.E.S.T. in France between 2004 and 2012 - Download this document for free, or read online. Document in PDF available to download.

Antimicrobial Resistance and Infection Control

, 3:36

First Online: 01 December 2014Received: 14 April 2014Accepted: 03 November 2014

Abstract

BackgroundClinically important Gram-positive and -negative isolates were collected from patients in France between 2004 and 2012 as a part of the Tigecycline Evaluation and Surveillance Trial.

MethodsMICs were determined using methodology described by the Clinical and Laboratory Standards Institute.

ResultsIn total, 17,135 isolates were contributed by 29 medical centres; respiratory 25.1% and cardiovascular 20.3% sources predominated. High susceptibility was observed among Enterococcus spp. and Staphylococcus aureus including methicillin-resistant S. aureus MRSA to linezolid 100%, tigecycline ≥99.8% and vancomycin ≥94.6%. The percentage of MRSA decreased from 34.3% in 2004 to 20.0% in 2009 before increasing to 34.7% in 2012. Vancomycin, linezolid, levofloxacin and carbapenems were highly active ≥99.6% against Streptococcus pneumoniae; 3.2% were PRSP. Escherichia coli showed peak susceptibility to the carbapenems ≥99.9%, tigecycline 99.3% and amikacin 97.9%; significant p < 0.01 decreases in susceptibility were observed for ampicillin, cefepime and ceftriaxone between 2004 and 2012. ESBL production among E. coli increased from 3.0% 2004 to 14.9% 2012. High susceptibility was noted among Haemophilus influenzae to levofloxacin 100%, amoxicillin-clavulanate 99.2%, carbapenems ≥98.7% and ceftriaxone 98.5%; β-lactamase production fluctuated with no notable trend between 18.1% 2007 and 27.7% 2011. Klebsiella spp. were highly susceptible to carbapenems ≥99.6% and amikacin ≥96.4%; significant p < 0.01 decreases in amoxicillin-clavulanate, cefepime, ceftriaxone, levofloxacin, piperacillin-tazobactam and tigecycline susceptibility were observed among K. pneumoniae between 2004 and 2012. Only imipenem was highly active 96.5% susceptible against Acinetobacter baumannii. Imipenem and amikacin 87.7% and 87.1% susceptible were the most active agents against P. aeruginosa; 10.2% of isolates were categorized as multidrug resistant.

ConclusionsCarbapenems, linezolid, tigecycline and vancomycin conserved good in vitro activity against most pathogens according to their spectrum of activity in France between 2004 and 2012.

KeywordsFrance Antimicrobial resistance Antimicrobial surveillance Multidrug resistance MDR Tigecycline Electronic supplementary materialThe online version of this article doi:10.1186-2047-2994-3-36 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Vincent Cattoir - Michael J Dowzicky

Source: https://link.springer.com/







Related documents